<DOC>
	<DOCNO>NCT00702780</DOCNO>
	<brief_summary>This study aim test whether escitalopram would slow brain atrophy patient mild moderate AD 52-week period .</brief_summary>
	<brief_title>Progression Delaying Effect Escitalopram Alzheimer 's Disease</brief_title>
	<detailed_description>- Study institution : Four university hospital Korea - Design : Multi-center , randomize , placebo-controlled , double-blind clinical trial - Subjects : 74 probable Alzheimer 's disease patient take donepezil stable dose within 2 month ( Escitalopram 37 : Placebo 37 )</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Age:40~90 year Education : illiterate Clinical Dementia Rating ( CDR ) :0.5~2 Modified Hachinski Ischemic Score ( Rosen et al. , 1979 ) : le 4 Dementia accord DSMIV criterion Probable Alzheimer 's disease accord NINCDSADRDA criterion Current ongoing donepezil medication stable dos ( 5 ~ 10 mg/day ) least 2 month Exclusion criterion : Evidence delirium , confusion alter consciousness Evidence Parkinson 's disease , stroke , brain tumor normal pressure hydrocephalus Evidence infectious inflammatory brain disease Evidence serious cerebrovascular disease Current major depressive disorder major psychiatric illness Evidence serious unstable medical illness significantly change cognitive state History alcohol substance dependence Any antidepressant medication within previous 4 week Absence reliable cooperative collateral informant Any condition prohibit MRI scan , presence pacemaker cerebrovascular clip , claustrophobia Evidence focal brain lesion MRI include lacunes white matter hyperintensity lesion grade 2 Fazeka scale</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>escitalopram</keyword>
	<keyword>MRI</keyword>
</DOC>